Ligand id: 9744

Name: emicizumab

Compound class Antibody
Approved drug? Yes (FDA (2017), EMA (2018))
International Nonproprietary Names
INN number INN
10115 emicizumab
ACE-910 | ACE910 | emicizumab-kxwh | Hemlibra® | RG6013
Emicizumab, is a humanised bispecific antibody that binds blood coagulation factors IXa and X and acts as a factor VIII mimetic to bring about activation of factor X, and promote coagulation [2-3,5]. In essence, emicizumab works by bridging between coagulation factors IX and X and is the first-in-class drug for haemophilia A prevention with this mechanism of action.
Database Links
Specialist databases
IMGT/mAb-DB 564
Other databases
GtoPdb PubChem SID 354702217
Search PubMed clinical trials emicizumab
Search PubMed titles emicizumab
Search PubMed titles/abstracts emicizumab